Estonia Has the Health Record. It Needs More Measurements.

I keep thinking about buying SYNLAB.

The fantasy begins with physical infrastructure. Blood collection points. Couriers moving samples through the night. Accredited laboratories. Sequencing machines. Pathology workflows. Hundreds of people who know how to turn a tube of blood into a medically defensible result.

Owning that network would create the ability to lower the cost of producing health data. It could support routine blood testing, genetics, cancer diagnostics and increasingly specialised forms of analysis. Each measurement could contribute to a longer view of how a person changes over time.

The idea becomes more complicated in Estonia because Estonia has already built much of the health-data infrastructure that other countries are still trying to assemble.

The national Health Information System has operated since 2008. It is a central database through which healthcare providers exchange information, and providers are obligated to submit relevant data. Patients can see their information through the Health Portal. The Ministry of Social Affairs controls the database, while TEHIK develops and manages it.

Estonia also has one of the world's most substantial population biobanks relative to the size of the country. More than 210,000 people, around one-fifth of the adult population, have joined the Estonian Biobank. Their genetic data can be linked with health records and national registries for approved research under a defined legal and ethical framework.

That changes the question.

Estonia does not need a private company to invent a separate national memory for health. It already has institutions responsible for holding, moving and governing medical information. A company that tried to replace those systems would duplicate public infrastructure and create a new concentration of sensitive data outside democratic control.

The opportunity sits closer to the body.

A health information system stores the measurements that healthcare produces. It cannot store the measurement that was never taken. It cannot show a ten-year trend from two isolated blood tests. It cannot identify a gradual change in a marker when testing only happens after symptoms appear or a doctor has a specific reason to investigate.

Estonia has built the record. The density of the record still depends on the physical machinery of medicine.

Laboratory data looks digital when it appears in a portal, but its production remains stubbornly material. Someone has to collect the sample correctly. The tube needs an identity, a temperature range and a route through the logistics network. Equipment needs calibration. Reagents need quality control. Results require validation. Laboratories need accreditation, trained staff and procedures that continue working at seven in the morning during flu season.

This is why buying an existing laboratory network feels different from launching a health app.

SYNLAB Eesti describes itself as Estonia's largest medical laboratory. According to its current company information, it handles around 16,000 sample materials each day, performs more than 8.5 million analyses annually, employs more than 400 people and operates 18 laboratories and sample collection points. It already provides services to family doctors, specialists, hospitals, occupational-health providers, public institutions and private customers.

The network already generates a large share of Estonia's biological measurements. Its current operating model is largely transactional. A test is ordered, a sample moves through the system, a result is validated and the answer is delivered.

A different ownership thesis could treat the laboratory as a measurement utility inside the national health system.

The public system would remain the common record. The laboratory network would focus on making clinically useful measurement cheaper, easier to access and more consistent. Results would flow into national infrastructure through shared standards. Patients would retain the access and protections provided by the public system. Researchers would work through governed environments rather than receiving an unrestricted commercial copy of the population.

The value would come from improving resolution.

A single cholesterol result is a point. Repeated results create a trajectory. The same principle applies to kidney function, liver function, inflammation, glucose regulation, blood-cell counts and many other biomarkers. When these measurements are combined with prescriptions, diagnoses, procedures, genomic information and outcomes, the health system gains a clearer view of change.

Change is often more informative than the absolute number.

A value can remain inside a reference range while moving steadily in an unfavourable direction. Another value can appear abnormal for one person while remaining stable and harmless across many years. Longitudinal context helps clinicians distinguish an emerging pattern from ordinary variation.

The infrastructure should support evidence-based testing programmes rather than unlimited panels sold through fear. More tests can generate false positives, incidental findings, anxiety and unnecessary procedures. A dense record becomes useful when measurement frequency, target populations and follow-up pathways are clinically justified.

This places medicine and governance at the centre of the business model.

The laboratory network would need protocols explaining which measurements deserve repetition, how often they should be taken, when a trend requires intervention and which results should never be interpreted without a clinician. Cancer screening requires especially careful standards because earlier detection can save lives while poorly targeted screening can also expose people to cascades of uncertain findings.

The same discipline applies to genetics. The Estonian Biobank already demonstrates the value of combining genomic information with health and registry data under a national framework. A commercial laboratory could expand sequencing and specialised diagnostics while contributing results through agreed interfaces and consent models. Its role would be measurement, validation and clinical delivery. The public and research institutions would continue governing population-level reuse.

This arrangement could create a productive tension between public infrastructure and private operational capability.

The state defines rights, standards, access rules and national priorities. Laboratories compete on cost, quality, accessibility, turnaround time and analytical capability. Universities develop and validate new methods. Hospitals and family doctors decide how those methods enter care. Citizens can see who accessed their information and decide where consent is required.

A national laboratory strategy could also reveal where private incentives are insufficient. Rural collection points, rare-disease diagnostics, pandemic capacity and population screening may require public procurement or long-term service agreements. The measurement layer starts to resemble other essential infrastructure: privately operated in places, publicly directed in others, and governed as a system because failure affects everyone.

Europe is moving toward a broader version of this architecture. The European Health Data Space entered into force on 26 March 2025. Its rules will gradually support cross-border access to health information and controlled secondary use for research, innovation and policy. Laboratory results are scheduled to become one of the priority data categories exchanged across member states from 2031.

A company such as SYNLAB already spans national borders. That gives the network a possible role beyond processing tests within each country. It could become a standardised European measurement layer capable of feeding national health systems while respecting their different governance structures.

The strategic asset would be operational interoperability.

A blood sample collected in Estonia, Finland or Germany should produce a result that can enter the relevant national record with consistent units, reference ranges, provenance and quality metadata. A repeated test should remain comparable across time and location. A researcher studying outcomes across countries should be able to understand how the measurement was produced without receiving direct access to a person's identity.

This is less glamorous than an AI doctor. It may be more foundational.

AI models can analyse patterns only after reliable data exists. Better prediction cannot compensate for years in which nobody measured the relevant variable. A health system with excellent digital records and sparse biological data can remember every encounter while still seeing the person at low resolution.

The ambition therefore needs to be framed carefully.

Owning a laboratory network should not provide ownership over the population's medical history. It should create responsibility for producing trustworthy measurements and delivering them into institutions built to govern health data in the public interest.

That responsibility would include refusing some tests, correcting misleading consumer interpretations, protecting people from unnecessary medicalisation and accepting that the most valuable dataset may remain outside the company's exclusive control.

This weakens the familiar technology story in which data ownership creates the moat. It strengthens a more durable infrastructure story. The moat becomes accreditation, logistics, trust, clinical integration, analytical quality, purchasing power and the ability to make a complex physical system work every day.

I still want to buy SYNLAB.

The reason is clearer now. Estonia already has a place for its medical memory. A transformed laboratory network could help that system observe the body with greater resolution, at lower cost and across a longer span of life.

Estonia has built the record.

The next task is to improve the measurements flowing into it.

Connected reading

• Your DNA Is Finished, but the Product Cannot Be
• Eleven Terabytes Are Not a Story
• The Report Is a Form
• The Real Bottleneck Is Human Attention

AI authorship note

This essay began with Kris Haamer's long-term goal of owning and operating a medical-grade laboratory network for blood, DNA and cancer analysis. The discussion moved through existing laboratory and longitudinal-data companies, the possibility of acquiring SYNLAB and the role of Estonia's national Health Information System and Biobank. AI helped research the public infrastructure, challenge an earlier company-centred framing, develop the measurement-layer thesis and implement the publication. Kris identified the national-system gap, directed the rewrite, selected the final argument and made the publication decision.